Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial
Authors
Keywords
-
Journal
LANCET
Volume 397, Issue 10290, Pages 2169-2181
Publisher
Elsevier BV
Online
2021-05-21
DOI
10.1016/s0140-6736(21)00589-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
- (2021) Emma Guttman-Yassky et al. LANCET
- Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
- (2020) E.L. Simpson et al. BRITISH JOURNAL OF DERMATOLOGY
- Neutrophils as emerging therapeutic targets
- (2020) Tamás Németh et al. NATURE REVIEWS DRUG DISCOVERY
- Shifting paradigms in the immunology of atopic dermatitis
- (2020) Dirk Jan Hijnen JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis
- (2020) Eric Simpson et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial
- (2020) David Rosmarin et al. LANCET
- Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis
- (2020) Jonathan I. Silverberg et al. JAMA Dermatology
- Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐naïve Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Randomized, Double‐blind, Active‐comparator, Multi‐center, Multi‐country Trial
- (2020) Ronald van Vollenhoven et al. Arthritis & Rheumatology
- Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial
- (2020) J.I. Silverberg et al. BRITISH JOURNAL OF DERMATOLOGY
- Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)
- (2020) A. Wollenberg et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis
- (2020) Kristian Reich et al. JAMA Dermatology
- Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
- (2019) Josef S Smolen et al. LANCET
- Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta‐analysis
- (2019) Linghong Guo et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial
- (2019) Emma Guttman-Yassky et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Eczema Herpeticum: Clinical and Pathophysiological Aspects
- (2019) Alexia Damour et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Atopic dermatitis
- (2018) Stephan Weidinger et al. Nature Reviews Disease Primers
- JAK Inhibitors for Atopic Dermatitis: An Update
- (2018) Helen He et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
- (2017) Andrew Blauvelt et al. LANCET
- Drug survival for azathioprine and enteric-coated mycophenolate sodium in a long-term daily practice cohort of adult patients with atopic dermatitis
- (2016) J. van der Schaft et al. BRITISH JOURNAL OF DERMATOLOGY
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
- (2016) Eric L. Simpson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis
- (2015) J. van der Schaft et al. BRITISH JOURNAL OF DERMATOLOGY
- Guidelines of care for the management of atopic dermatitis
- (2014) Lawrence F. Eichenfield et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The Global Burden of Skin Disease in 2010: An Analysis of the Prevalence and Impact of Skin Conditions
- (2013) Roderick J. Hay et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now